|
1
|
Friedl P and Wolf K: Plasticity of cell
migration: A multiscale tuning model. J Cell Biol. 188:11–19. 2010.
View Article : Google Scholar :
|
|
2
|
Martin NE, Mucci LA, Loda M and Depinho
RA: Prognostic determinants in prostate cancer. Cancer J.
17:429–437. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kim SH, Hwang KA, Shim SM and Choi KC:
Growth and migration of LNCaP prostate cancer cells are promoted by
triclosan and benzophenone-1 via an androgen receptor signaling
pathway. Environ Toxicol Pharmacol. 39:568–576. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Quail DF and Joyce JA: Microenvironmental
regulation of tumor progression and metastasis. Nat Med.
19:1423–1437. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yilmaz M and Christofori G: Mechanisms of
motility in metastasizing cells. Mol Cancer Res. 8:629–642. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Thuaud F, Ribeiro N, Nebigil CG and
Désaubry L: Prohibitin ligands in cell death and survival: Mode of
action and therapeutic potential. Chem Biol. 20:316–331. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kowno M, Watanabe-Susaki K, Ishimine H,
Komazaki S, Enomoto K, Seki Y, Wang YY, Ishigaki Y, Ninomiya N,
Noguchi TA, et al: Prohibitin 2 regulates the proliferation and
lineage-specific differentiation of mouse embryonic stem cells in
mitochondria. PLoS One. 9:e815522014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yoshimaru T, Komatsu M, Matsuo T, Chen YA,
Murakami Y, Mizuguchi K, Mizohata E, Inoue T, Akiyama M, Yamaguchi
R, et al: Targeting BIG3-PHB2 interaction to overcome tamoxifen
resistance in breast cancer cells. Nat Commun. 4:24432013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chowdhury I, Garcia-Barrio M, Harp D,
Thomas K, Matthews R and Thompson WE: The emerging roles of
prohibitins in folliculogenesis. Front Biosci (Elite Ed).
4:690–699. 2012. View
Article : Google Scholar
|
|
10
|
Sievers C, Billig G, Gottschalk K and
Rudel T: Prohibitins are required for cancer cell proliferation and
adhesion. PLoS One. 5:e127352010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yurugi H and Rajalingam K: A role for
prohibitin in mast cell activation: Location matters. Sci Signal.
6:pe292013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cheng J, Gao F, Chen X, Wu J, Xing C, Lv
Z, Xu W, Xie Q, Wu L, Ye S, et al: Prohibitin-2 promotes
hepatocellular carcinoma malignancy progression in hypoxia based on
a label-free quantitative proteomics strategy. Mol Carcinog.
53:820–832. 2014. View
Article : Google Scholar
|
|
13
|
Pabona JM, Velarde MC, Zeng Z, Simmen FA
and Simmen RC: Nuclear receptor co-regulator Krüppel-like factor 9
and prohibitin 2 expression in estrogen-induced epithelial cell
proliferation in the mouse uterus. J Endocrinol. 200:63–73. 2009.
View Article : Google Scholar
|
|
14
|
Van Aken O, Whelan J and Van Breusegem F:
Prohibitins: Mitochondrial partners in development and stress
response. Trends Plant Sci. 15:275–282. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Polier G, Neumann J, Thuaud F, Ribeiro N,
Gelhaus C, Schmidt H, Giaisi M, Köhler R, Müller WW, Proksch P, et
al: The natural anticancer compounds rocaglamides inhibit the
Raf-MEK-ERK pathway by targeting prohibitin 1 and 2. Chem Biol.
19:1093–1104. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhu B, Zhai J, Zhu H and Kyprianou N:
Prohibitin regulates TGF-β induced apoptosis as a downstream
effector of Smad-dependent and -independent signaling. Prostate.
70:17–26. 2010. View Article : Google Scholar
|
|
17
|
Chen RX, Song HY, Dong YY, Hu C, Zheng QD,
Xue TC, Liu XH, Zhang Y, Chen J, Ren ZG, et al: Dynamic expression
patterns of differential proteins during early invasion of
hepatocellular carcinoma. PLoS One. 9:e885432014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fu P, Yang Z and Bach LA: Prohibitin-2
binding modulates insulin-like growth factor-binding protein-6
(IGFBP-6)-induced rhabdomyosarcoma cell migration. J Biol Chem.
288:29890–29900. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vivanco I, Chen ZC, Tanos B, Oldrini B,
Hsieh WY, Yannuzzi N, Campos C and Mellinghoff IK: A
kinase-independent function of AKT promotes cancer cell survival.
eLife. 3:e037512014. View Article : Google Scholar
|
|
20
|
Kang W, Tong JHM, Lung RWM, Dong Y, Yang
W, Pan Y, Lau KM, Yu J, Cheng AS and To KF: let-7b/g silencing
activates AKT signaling to promote gastric carcinogenesis. J Transl
Med. 12:2812014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liang JW, Shi ZZ, Shen TY, Che X, Wang Z,
Shi SS, Xu X, Cai Y, Zhao P, Wang CF, et al: Identification of
genomic alterations in pancreatic cancer using array-based
comparative genomic hybridization. PLoS One. 9:e1146162014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chin YR, Yuan X, Balk SP and Toker A:
PTEN-deficient tumors depend on AKT2 for maintenance and survival.
Cancer Discov. 4:942–955. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Virtakoivu R, Pellinen T, Rantala JK,
Perälä M and Ivaska J: Distinct roles of AKT isoforms in regulating
β1-integrin activity, migration, and invasion in prostate cancer.
Mol Biol Cell. 23:3357–3369. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhou GL, Tucker DF, Bae SS, Bhatheja K,
Birnbaum MJ and Field J: Opposing roles for Akt1 and Akt2 in
Rac/Pak signaling and cell migration. J Biol Chem. 281:36443–36453.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fortier AM, Van Themsche C, Asselin E and
Cadrin M: Akt isoforms regulate intermediate filament protein
levels in epithelial carcinoma cells. FEBS Lett. 584:984–988. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cariaga-Martinez AE, López-Ruiz P,
Nombela-Blanco MP, Motiño O, González-Corpas A, Rodriguez-Ubreva J,
Lobo MV, Cortés MA and Colás B: Distinct and specific roles of AKT1
and AKT2 in androgen-sensitive and androgen-independent prostate
cancer cells. Cell Signal. 25:1586–1597. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Héron-Milhavet L, Mamaeva D, Rochat A,
Lamb NJ and Fernandez A: Akt2 is implicated in skeletal muscle
differentiation and specifically binds Prohibitin2/REA. J Cell
Physiol. 214:158–165. 2008. View Article : Google Scholar
|
|
28
|
Gardner S, Anguiano M and Rotwein P:
Defining Akt actions in muscle differentiation. Am J Physiol Cell
Physiol. 303:C1292–C1300. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Matheny RW Jr and Adamo ML: Effects of
PI3K catalytic subunit and Akt isoform deficiency on mTOR and
p70S6K activation in myoblasts. Biochem Biophys Res Commun.
390:252–257. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rhodes DR, Kalyana-Sundaram S, Mahavisno
V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ,
Kincead-Beal C, Kulkarni P, et al: Oncomine 3.0: genes, pathways,
and networks in a collection of 18,000 cancer gene expression
profiles. Neoplasia. 9:166–180. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rhodes DR, Yu J, Shanker K, Deshpande N,
Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM:
ONCOMINE: a cancer microarray database and integrated data-mining
platform. Neoplasia. 6:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang Z, Wang L, Mei M, Zhu Y, Du X, Lee
C, Park I, Zhang J and Shi J: Both nongenomic and genomic effects
are involved in estradiol's enhancing the phenotype of smooth
muscle cells in cultured prostate stromal cells. Prostate.
70:317–332. 2010.
|
|
33
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
34
|
Héron-Milhavet L, Franckhauser C, Rana V,
Berthenet C, Fisher D, Hemmings BA, Fernandez A and Lamb NJ: Only
Akt1 is required for proliferation, while Akt2 promotes cell cycle
exit through p21 binding. Mol Cell Biol. 26:8267–8280. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yarrow JC, Perlman ZE, Westwood NJ and
Mitchison TJ: A high-throughput cell migration assay using scratch
wound healing, a comparison of image-based readout methods. BMC
Biotechnol. 4:21. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Artal-Sanz M and Tavernarakis N:
Prohibitin and mitochondrial biology. Trends Endocrinol Metab.
20:394–401. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Du XL, Yu L, Ning ZC, et al: Estrogen
receptor inhibitor, REA, have an effect on proliferation and
migration in prostate cancer cells. Acta Scientiarum Naturalium
Universitatis Nankaiensis. 46:36–43. 2013.
|
|
38
|
Irie HY, Pearline RV, Grueneberg D, Hsia
M, Ravichandran P, Kothari N, Natesan S and Brugge JS: Distinct
roles of Akt1 and Akt2 in regulating cell migration and
epithelial-mesenchymal transition. J Cell Biol. 171:1023–1034.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dillon RL, Marcotte R, Hennessy BT,
Woodgett JR, Mills GB and Muller WJ: Akt1 and akt2 play distinct
roles in the initiation and metastatic phases of mammary tumor
progression. Cancer Res. 69:5057–5064. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Welsh JB, Sapinoso LM, Su AI, Kern SG,
Wang-Rodriguez J, Moskaluk CA, Frierson HF Jr and Hampton GM:
Analysis of gene expression identifies candidate markers and
pharmacological targets in prostate cancer. Cancer Res.
61:5974–5978. 2001.PubMed/NCBI
|
|
41
|
Singh D, Febbo PG, Ross K, Jackson DG,
Manola J, Ladd C, Tamayo P, Renshaw AA, D'Amico AV, Richie JP, et
al: Gene expression correlates of clinical prostate cancer
behavior. Cancer Cell. 1:203–209. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lapointe J, Li C, Higgins JP, van de Rijn
M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim
U, Ekman P, et al: Gene expression profiling identifies clinically
relevant subtypes of prostate cancer. Proc Natl Acad Sci USA.
101:811–816. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Varambally S, Yu J, Laxman B, Rhodes DR,
Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ, Wei
JT, et al: Integrative genomic and proteomic analysis of prostate
cancer reveals signatures of metastatic progression. Cancer Cell.
8:393–406. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Liu P, Ramachandran S, Ali Seyed M,
Scharer CD, Laycock N, Dalton WB, Williams H, Karanam S, Datta MW,
Jaye DL and Moreno CS: Sex-determining region Y box 4 is a
transforming oncogene in human prostate cancer cells. Cancer Res.
66:4011–4019. 2006. View Article : Google Scholar : PubMed/NCBI
|
